CRN01941
Neuroendocrine Tumors (NETs)
PreclinicalResearch
Key Facts
Indication
Neuroendocrine Tumors (NETs)
Phase
Preclinical
Status
Research
Company
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is building a premier, endocrine-rooted global pharmaceutical company dedicated to improving the lives of patients with endocrine disorders. Founded by scientists with a proven track record in GPCR drug discovery, the company has advanced a pipeline of novel, oral nonpeptide therapies targeting significant unmet needs. With a lead program in Phase 3 for acromegaly and a growing pipeline, Crinetics is positioned to become a leader in next-generation endocrine care.
View full company profile